Selective HIF stabilization alleviates hepatocellular steatosis and ballooning in a rodent model of 70% liver resection. Issue 19 (15th October 2021)
- Record Type:
- Journal Article
- Title:
- Selective HIF stabilization alleviates hepatocellular steatosis and ballooning in a rodent model of 70% liver resection. Issue 19 (15th October 2021)
- Main Title:
- Selective HIF stabilization alleviates hepatocellular steatosis and ballooning in a rodent model of 70% liver resection
- Authors:
- Iesari, Samuele
Leclercq, Isabelle
Joudiou, Nicolas
Komuta, Mina
Daumerie, Aurélie
Ambroise, Jérôme
Dili, Alexandra
Feza-Bingi, Natacha
Xhema, Daela
Bouzin, Caroline
Gallez, Bernard
Pisani, Francesco
Bonaccorsi-Riani, Eliano
Gianello, Pierre - Abstract:
- Abstract: Background: Small-for-size syndrome (SFSS) looms over patients needing liver resection or living-donor transplantation. Hypoxia has been shown to be crucial for the successful outcome of liver resection in the very early postoperative phase. While poorly acceptable as such in real-world clinical practice, hypoxia responses can still be simulated by pharmacologically raising levels of its transducers, the hypoxia-inducible factors (HIFs). We aimed to assess the potential role of a selective inhibitor of HIF degradation in 70% hepatectomy (70%Hx). Methods: In a pilot study, we tested the required dose of roxadustat to stabilize liver HIF1α. We then performed 70%Hx in 8-week-old male Lewis rats and administered 25 mg/kg of roxadustat (RXD25) at the end of the procedure. Regeneration was assessed: ki67 and 5-ethynyl-2′-deoxyuridine (EdU) immunofluorescent labeling, and histological parameters. We also assessed liver function via a blood panel and functional gadoxetate-enhanced magnetic resonance imaging (MRI), up to 47 h after the procedure. Metabolic results were analyzed by means of RNA sequencing (RNAseq). Results: Roxadustat effectively increased early HIF1α transactivity. Liver function did not appear to be improved nor liver regeneration to be accelerated by the experimental compound. However, treated livers showed a mitigation in hepatocellular steatosis and ballooning, known markers of cellular stress after liver resection. RNAseq confirmed that roxadustatAbstract: Background: Small-for-size syndrome (SFSS) looms over patients needing liver resection or living-donor transplantation. Hypoxia has been shown to be crucial for the successful outcome of liver resection in the very early postoperative phase. While poorly acceptable as such in real-world clinical practice, hypoxia responses can still be simulated by pharmacologically raising levels of its transducers, the hypoxia-inducible factors (HIFs). We aimed to assess the potential role of a selective inhibitor of HIF degradation in 70% hepatectomy (70%Hx). Methods: In a pilot study, we tested the required dose of roxadustat to stabilize liver HIF1α. We then performed 70%Hx in 8-week-old male Lewis rats and administered 25 mg/kg of roxadustat (RXD25) at the end of the procedure. Regeneration was assessed: ki67 and 5-ethynyl-2′-deoxyuridine (EdU) immunofluorescent labeling, and histological parameters. We also assessed liver function via a blood panel and functional gadoxetate-enhanced magnetic resonance imaging (MRI), up to 47 h after the procedure. Metabolic results were analyzed by means of RNA sequencing (RNAseq). Results: Roxadustat effectively increased early HIF1α transactivity. Liver function did not appear to be improved nor liver regeneration to be accelerated by the experimental compound. However, treated livers showed a mitigation in hepatocellular steatosis and ballooning, known markers of cellular stress after liver resection. RNAseq confirmed that roxadustat unexpectedly increases lipid breakdown and cellular respiration. Conclusions: Selective HIF stabilization did not result in an enhanced liver function after standard liver resection, but it induced interesting metabolic changes that are worth studying for their possible role in extended liver resections and fatty liver diseases. … (more)
- Is Part Of:
- Clinical science. Volume 135:Issue 19(2021)
- Journal:
- Clinical science
- Issue:
- Volume 135:Issue 19(2021)
- Issue Display:
- Volume 135, Issue 19 (2021)
- Year:
- 2021
- Volume:
- 135
- Issue:
- 19
- Issue Sort Value:
- 2021-0135-0019-0000
- Page Start:
- 2285
- Page End:
- 2305
- Publication Date:
- 2021-10-15
- Subjects:
- hepatocellular ballooning -- hepatocellular steatosis -- hypoxia-inducible factors -- liver regeneration -- liver resection -- prolyl hydroxylase domain protein inhibitors
Medicine -- Periodicals
Biochemistry -- Periodicals
616 - Journal URLs:
- https://portlandpress.com/clinsci ↗
- DOI:
- 10.1042/CS20210183 ↗
- Languages:
- English
- ISSNs:
- 0143-5221
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 19737.xml